Dr Anna Perdrix Rosell
Sixfold Bioscience Ltd., London, United Kingdom
Anna Perdix Rosell is Managing Director and leads Sixfold Bioscience’s R&D team.
Anna Perdrix Rosell is currently the Managing Director at Sixfold Bioscience, where she leads a multidisciplinary team of scientists at the interface of biology, chemistry and computation. After graduating from University of Barcelona with a BSc in Biomedical Sciences, Anna went on to complete her MRes in Translational Cancer Medicine at King’s College London and PhD in Cancer Research at the Francis Crick Institute, London. She complemented her scientific training with an MBA.
During her doctoral studies she became deeply interested in science translation and co-founded Sixfold Bioscience together with a PhD graduate from the University of Cambridge. Sixfold is a venture-backed start-up at the forefront of developing an oligonucleotide-based therapeutic delivery platform for RNA Therapeutics.
Her scientific contributions have been published in prestigious journals (e.g. Current Biology, Cell and Nature Medicine) and have led to multiple patent applications. Dr. Perdrix Rosell is lead investigator in 10+ grants awarded by H2020 and UK funding bodies, including leading multi-million pan-european consortiums, and is a current Royal Academy of Engineering SME Leader, and member of the Advisory Board of the EPSRC funded Portabolomics consortium. Her scientific entrepreneurial journey has been recognised by Forbes on the 30 under 30 Science and Healthcare list (2018)), by Cancer Research UK and The Francis Crick Institute as a Future Science Leader (2018), by The Guardian as a Rising Star of Science (2019) and by The Maserati & The Sunday Times Top 100 British Entrepreneurs (2019).
We founded Sixfold to tackle the biggest challenge in healthcare: how to safely deliver therapeutics to diseased cells. Motivated by the impact our technology could make, we’ve been working hard in the lab and are now looking for a PhD student to help modulate the biological activity of our PODS technology. We’re proud of the company we’ve built and our team is Sixfold’s biggest competitive advantage. Our team is creative and iterates fast because they want to see their work make a difference in the clinic. If you want to help cure the incurable, you belong with us.
Diversity and inclusion
It’s important to mention that although disease affects us all, our industry still displays a huge lack of diversity — this needs to change. Our founding team is composed of many different nationalities, cultures and our board is 2/3rds female. Our goal is to create a company culture that promotes ideas and the inclusion of team members from all backgrounds. That means we have no judgement when it comes to any one of the things that make you who you are — your gender, ethnicity, sexuality, religion or your secret aversion to cucumber water.